TherapeuticsMD
→
Mayne Pharma
License/Asset Acquisition · Cash (license/asset) · MYX · announced Dec 4, 2022
Announced
Dec 4, 2022
Closed
Dec 30, 2022
Economics
Cash (license/asset)()
Pre-deal · pre-deal mark: 2022, year precision · rounding grid ±$100M · Mayne Pharma press release — TherapeuticsMD acquisition, 2023
$140M upfront license + $13.1M working capital + up to $30M milestones + 20-year royalties
Target
TherapeuticsMD
Reproductive Health · Clinical / therapeutic
HQ Boca Raton, FL · Founded 2008
Women's health hormone therapy — BIJUVA (bio-identical estradiol/progesterone for menopause), ANNOVERA (contraceptive vaginal ring), IMVEXXY (estradiol vaginal inserts); $153M total consideration
- Business Wire — TherapeuticsMD press release (Jan 3, 2023)
- SEC EDGAR — TherapeuticsMD 8-K (Dec 30, 2022)
Acquirer
Mayne Pharma (MYX)
Reproductive Health
HQ Melbourne, Australia
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Exclusive US rights to BIJUVA (menopause), ANNOVERA (contraception), and IMVEXXY (vaginal atrophy) — establishes Mayne Pharma in women's health hormone therapy
Evidence ladder
Secondary (press / IR)
Business Wire — TherapeuticsMD press release (Jan 3, 2023)
Primary (regulatory / filing)
SEC EDGAR 8-K (Jan 3, 2023
SEC EDGAR filings (ticker locator)Tertiary (trade / analyst)
closing effective Dec 30, 2022)
Primary (regulatory / filing)
SEC EDGAR 8-K EX-99.1 (TherapeuticsMD, Dec 4, 2022 — definitive agreements) https://www.sec.gov/Archives/edgar/data/25743/000119312522298002/d409080dex991.htm
Open sourcePrimary (regulatory / filing)
SEC EDGAR 8-K (TherapeuticsMD, Jan 3, 2023 — closing effective Dec 30, 2022) https://www.sec.gov/Archives/edgar/data/25743/000119312523000222/d417698d8k.htm
Open source
Limitations
- $140M upfront license + $13.1M working capital + up to $30M milestones + 20-year royalties
- Pre-deal valuation sourced from: Mayne Pharma press release — TherapeuticsMD acquisition, 2023. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Reproductive Health
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
Insufficient disclosed data
No verified Reproductive Health deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.
Other verified deals by Mayne Pharma
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by Mayne Pharma are already listed above, or none are in the dataset.
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — TherapeuticsMD (Reproductive Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 5 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.